STOCK TITAN

Crinetics Pharmaceuticals Inc - CRNX STOCK NEWS

Welcome to our dedicated news page for Crinetics Pharmaceuticals (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Crinetics Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Crinetics Pharmaceuticals's position in the market.

Rhea-AI Summary
Crinetics Pharmaceuticals announces pricing of upsized public offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.7%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals plans to offer $250.0 million of common stock in a public offering, with an option for underwriters to purchase an additional $37.5 million. Proceeds will fund the development of paltusotine, CRN04894, and other R&D programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.29%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals grants non-qualified stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
63.31%
Tags
none
Rhea-AI Summary
Crinetics Pharmaceuticals announces positive results from Phase 3 PATHFNDR-1 study for paltusotine in acromegaly patients. 83% of participants maintained IGF-1 ≤1.0 xULN vs. 4% on placebo. Mean IGF-1 levels and symptom diary scores were maintained. Paltusotine was well-tolerated with no severe or serious adverse events. Conference call scheduled for September 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. reported financial results for Q2 2023. The company expects to release topline data from its Phase 3 PATHFNDR-1 study in September 2023, providing insight into paltusotine's potential as an alternative treatment for acromegaly. Enrollment in the Phase 3 PATHFNDR-2 study is complete, with topline results expected in Q1 2024. However, the company has suspended development of its CRN04777 program due to nonclinical profile concerns. Crinetics plans to submit a new drug application for paltusotine in acromegaly in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) will host a Key Opinion Leader (KOL) webinar featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital. They will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands (SRLs). The Crinetics management team will also discuss its pipeline of internally discovered oral small molecule drug candidates, with a focus on the Phase 3 PATHFNDR-1 study of paltusotine, an investigational, once-daily oral small molecule somatostatin receptor type 2 agonist.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
Crinetics Pharmaceuticals Inc

Nasdaq:CRNX

CRNX Rankings

CRNX Stock Data

3.47B
64.74M
1.92%
97.19%
6.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Diego

About CRNX

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.